Quality of Life of Chronic Hepatitis B Patients Consuming Nucleoside Analog: A Case-Control Clinical Study in Indonesia
Downloads
Introduction: Chronic hepatitis B raises serious concern due to its high morbidity, such as cirrhosis and hepatocellular carcinoma, and mortality from 267 per 100,000 person-years. Up to now, medical therapy that successfully eradicates the hepatitis B virus is not available. Therapy is given in the long term for suppressing viral replication and disease progression. Nucleoside analog (NA) is a medication that is consumed orally once a day for years. Previous studies showed that patients who were treated with NA had a different quality of life (QoL) compared to naí¯ve patients. This research aimed to analyze the QoL of chronic hepatitis B patients who consumed NA by comparing it with naí¯ve patients at Dr. Soetomo General Academic Hospital Surabaya.
Methods: Subjects were recruited consecutively from chronic hepatitis B patients at Dr. Soetomo General Academic Hospital Surabaya during 9 February – 31 May 2021. Data about sociodemographic characteristics, hepatitis B therapy history, and QoL were gained by using the SF-36 questionnaire and medical records. Subjects were divided into NA and naí¯ve groups which responses underwent an analytical comparison.
Results: NA group had significantly higher QoL in a physical component score (PCS) and mental component score (MCS), with physical functioning (PF), role limitations due to physical health (RP), role limitations due to emotional problems (RM), energy/fatigue (VT), emotional well-being (MH), social functioning (SF), and general health perception (GH) subscales having p<0.05
Conclusion: The QoL of patients who were treated with NA was significantly higher than that of naí¯ve patients in terms of physical and mental components.
Jefferies M, Rauff B, Rashid H, et al. Update on Global Epidemiology of Viral Hepatitis and Preventive Strategies. World J Clin Cases. 2018; 6: 589–599.
Data and Information Center. Situasi dan Analisis Hepatitis. Ministry of Health Republic of Indonesia. 2014 September [cited 2021 September 9]. Available from: URL: https://pusdatin.kemkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-hepatitis.pdf.
Muljono DH. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian J Hepato-Gastroenterology. 2017; 7: 55–59.
Yano Y, Utsumi T, Lusida MI, et al. Hepatitis B virus Infection in Indonesia. World J Gastroenterol. 2015; 21: 10714–10720.
Idilman R. The Summarized of EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Turkish J Gastroenterol. 2017; 28: 412–416.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018; 67: 1560–1599.
Gani RA, Hasan I, Djumhana A, et al. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia. Proceedings of The 19th Scientific Meeting of InaASL: 2012 Oct 14; Jakarta, Indonesia. Perhimpunan Peneliti Hati Indonesia; 2012.
Menéndez-Arias L, Álvarez M, Pacheco B. Nucleoside/nucleotide Analog Inhibitors of Hepatitis B Virus Polymerase: Mechanism of Action and Resistance. Curr Opin Virol 2014; 8: 1–9.
Lampertico P, Agarwal K, Berg T, et al. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. J Hepatol 2012; 57: 167–185.
World Health Organization. WHOQOL: Measuring Quality of Life. 2020 [cited 2021 September 9]. Available from: URL: https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/.
European Patients' Academy. Measuring Health-related quality of life (HRQoL). 2016 [cited 2021 September 9]. Available from: URL: http://www.patientsacademy.eu/health-technology-assessment/measuring-health-related-quality-life-hrqol/.
Rachmawati Y, Perwitasari DA, Adnan. Validasi Kuesioner Sf-36 Versi Indonesia. Pharmacy. 2014; 11: 14–25.
Trisnaningtyas RW, Sari CP, Setyaningrum N. Evaluasi Terapi pada Pasien Hepatitis B di RSUP Dr. Sardjito Yogyakarta. J Ilm Farm. 2017; 13: 29–34.
Janahi EM. Prevalence and Risk Factors of Hepatitis B Virus Infection in Bahrain, 2000 Through 2010. PLoS One. 2014; 9(2): e87599.
Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?. Front Immunol. 2018; 9: 1–7.
Ishihara Y, Takemoto T, Ishida A, et al. Protective Actions of 17 β -Estradiol and Progesterone on Oxidative Neuronal Injury Induced by Organometallic Compounds. Oxid Med Cell Longev. 2015. DOI: 10.1155/2015/343706.
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its Implications in Infectious Diseases. Biomol Concepts. 2018; 9: 64–79.
Raharjo MBS. Karakteristik Penderita Hepatitis B Rawat Inap di Rumah Sakit Umum Daerah Dr. Pirngadi Medan Tahun 2015-2016. Repositori Institusi Universitas Sumatera Utara. 2017 [cited 2021 September 10]. Available from: URL: https://repositori.usu.ac.id/handle/123456789/1738.
Ismayani. Karakteristik Penderita Hepatitis B yang Dirawat Inap di Rumah Sakit Umum Pusat Haji Adam Malik Medan Tahun 2015-2017. Repositori Institusi Universitas Sumatera Utara. 2018 [cited 2021 September 10]. Available from: URL: https://repositori.usu.ac.id/handle/123456789/13419.
Ministry of Health Republic of Indonesia. Inilah Upaya Negara Melindungi Generasi Bangsa dari Ancaman Penyakit Berbahaya. 2018 January [cited 2021 September 10]. Available from: URL: https://www.kemkes.go.id/article/print/18011500006/inilah-upaya-negara-melindungi-generasi-bangsa-dari-ancaman-penyakit-berbahaya.html.
Zulfian Z, Setiawati OR, Sapitia A. Hubungan Tingkat Pengetahuan Ibu Hamil Dengan Kejadian Hepatitis B Di Puskesmas Beringin Kecamatan Lubai Kota Palembang. J Ilmu Kedokt dan Kesehat. 2019; 5: 224–231.
Ministry of Health Republic of Indonesia. Formularium Nasional. 2019 December [cited 2021 September 10]. Available from: URL: https://iaijatim.id/wp-content/uploads/2020/01/KMK-No.-HK.01.07-MENKES-813-2019-ttg-Formularium-Nasional.pdf.
Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B: A 2012 update. Hepatol Int. 2012; 6(3): 531-561.
Xue X, Cai S, Ou H, et al. Health-related Quality of Life in Patients with Chronic Hepatitis B during Antiviral Treatment and Off-treatment. Patient Prefer Adherence. 2017; 11: 85–93.
Simonetti G, Gitto S, Golfieri L, et al. Quality of Life of Hepatitis B virus Surface Antigen-positive Patients with Suppressed Viral replication: Comparison between Inactive Carriers and Nucleot(s)ide Analog-treated Patients. Eur J Gastroenterol Hepatol. 2018; 30: 14–20.
Karacaer Z, Cakir B, Erdem H, et al. Quality of Life and Related Factors Among Chronic Hepatitis B-infected Patients: A multi-center study, Turkey. Health Qual Life Outcomes. 2016; 14: 153.
Milanović Z, Pantelić S, Trajković N, et al. Age-related Decrease in Physical Activity and Functional Fitness Among Elderly Men and Women. Clin Interv Aging. 2013; 8: 549–556.
Bao XY, Xie YX, Zhang XX, et al. The Association between Multimorbidity and Health-related Quality of Life: a Cross-sectional Survey Among Community Middle-aged and Elderly Residents in Southern China. Health Qual Life Outcomes. 2019; 17: 1–9.
Okviasanti F, Anggraini DA, Purnomo AC. Acute Pain Nursing Care in Patient With Hepatitis B: a Case Study. J Vocat Nurs. 2021; 2: 80.
Mills SEE, Nicolson KP, Smith BH. Chronic Pain: a Review of its Epidemiology and Associated Factors in Population-based Studies. Br J Anaesth. 2019; 123: 273–283.
Valizadeh L, Zamanzadeh V, Negarandeh R, et al. Psychological Reactions among Patients with Chronic Hepatitis B: a Qualitative Study. J Caring Sci. 2016; 5: 57–66.
Abdo AA. Health-related Quality of Life of Saudi Hepatitis B and C Patients. Ann Saudi Med. 2012; 32: 397–403.
Wunsch E, Koziarska D, Milkiewicz M, et al. In Patients with Liver Cirrhosis, Proinflammatory Interleukins Correlate with Health-related Quality of Life Irrespective of Minimal Hepatic Encephalopathy. Eur J Gastroenterol Hepatol. 2013; 25: 1402–1407.
Copyright (c) 2022 Natasya Ariesta Selyardi Putri, R. Haryanto Aswin, Izzatul Fithriyah, Ummi Maimunah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
